WO2001032690A1 - Substituted dipeptides having nos inhibiting activity - Google Patents
Substituted dipeptides having nos inhibiting activity Download PDFInfo
- Publication number
- WO2001032690A1 WO2001032690A1 PCT/JP2000/007579 JP0007579W WO0132690A1 WO 2001032690 A1 WO2001032690 A1 WO 2001032690A1 JP 0007579 W JP0007579 W JP 0007579W WO 0132690 A1 WO0132690 A1 WO 0132690A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- amino
- pharmaceutically acceptable
- alkyl
- acceptable salt
- Prior art date
Links
- 0 CCC(*C(*)*(C1)C1O)N Chemical compound CCC(*C(*)*(C1)C1O)N 0.000 description 2
- ALIUTJLNLCPCCD-UHFFFAOYSA-N CC(C(C(O)=O)NC)c1ncccc1 Chemical compound CC(C(C(O)=O)NC)c1ncccc1 ALIUTJLNLCPCCD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
Definitions
- This invention relates to new peptide compounds and pharmaceutically acceptable salts thereof which are useful as medicament.
- Some peptide compounds have been known as described in, for example, EP 0 394 989 A2, W096/16981 and JP-A-10-81671.
- This invention relates to new peptide compounds.
- One object of this invention is to provide the new and useful peptide compounds and pharmaceutically acceptable salts thereof that possess a strong inhibitory activity on the production of nitric oxide (NO).
- Another object of this invention is to provide a process for the preparation of the peptide compounds and salts thereof.
- a further object of this invention is to provide a pharmaceutical composition comprising said peptide compound or a pharmaceutically acceptable salt thereof.
- Still further object of this invention is to provide a use of said amide compounds or pharmaceutically acceptable salts thereof as a medicament for prophylactic and therapeutic treatment of NO-mediated diseases including respiratory diseases such as adult respiratory distress syndrome (ARDS) and asthma; cardiovascular diseases such as cardiovascular ischemia, myocarditis, heart failure, hypotension and atherosclerosis; endocrine diseases such as diabetes (e.g., insulin-dependent diabetes mellitus, etc.), complications of diabetes mellitus (e.g., diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, etc.) and gout; renal diseases such as glomerulonephritis and renal failure; gastrointestinal diseases such as peptic ulcer and inflammatory bowel disease (e.g., ulcerative colitis, chronic colitis, etc.); pancreatic diseases such as pancreatitis; hepatic diseases such as hepatitis and liver cirrhosis; diseases of bone or joint such as synovitis, arthritis, osteoarthritis, osteoporosis
- R 1 is benzofuranyl substituted by halogen, or styryl substituted by halogen,
- R 2 is phenyl, pyridyl, thienyl or thiazolyl, each of which is optionally substituted by one or more substituents selected from the group consisting of lower alkyl, lower alkoxy, halogen and trihalo( lower)alkyl, or lower alkyl optionally substituted by one or more halogen atoms,
- R 3 is hydrogen or lower alkoxy
- R 4 and R 5 are the same or different and each is hydrogen, lower alkyl or optionally protected hydroxy(lower)alkyl, and
- R 6 is hydrogen or lower alkyl.
- Suitable pharmaceutically acceptable salts of the object compound (I) are conventional non-toxic salts and include, for example, a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g., triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.); an inorganic acid addition salt (e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.); an organic carboxylic or sulfonic acid addition salt (e.g., formate, acetate, trifluoroacetate, maleate
- lower is used to intend a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise provided.
- Suitable "halogen” includes, for example, fluorine, bromine, chlorine and iodine.
- “Styryl substituted by halogen” means styryl which has halogen atom as a substituent on the benzene ring. Suitable examples of “styryl substituted by halogen” include 2- (2- chlorophenyl)ethenyl, 2-(3-chlorophenyl)ethenyl, 2-(4- chlorophenyl)ethenyl, 2- (2-bromophenyl) ethenyl, 2- (3- bromopheny1 )ethenyl, 2- ( 4-bromopheny1 )ethenyl , 2- ( 2- fluorophenyl )ethenyl, 2- (3-fluorophenyl) ethenyl, 2-(4- fluorophenyl )ethenyl, and the like.
- Suitable "lower alkyl” and “lower alkyl” moiety in the terms "trihalo( lower)alkyl” and “hydroxy(lower)alkyl” include straight or branched alkyl having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl and hexyl, in which more preferred one is alkyl.
- Suitable "lower alkoxy” includes straight or branched alkoxy having 1 to 6 carbon atom(s), such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, tert-pentyloxy and hexyloxy, in which more preferred one is C 1 -C 4 alkoxy.
- trihalo( lower) alkyl examples include trifluoromethyl , trichloromethyl, tribromomethyl , 2,2,2- trifluoroethyl and 3,3,3-trifluoropropyl, in which more preferred one is trifluoromethyl.
- “Lower alkyl optionally substituted by one or more halogen atoms” includes lower alkyl and halo ( lower)alkyl.
- Suitable “halo(lower)alkyl” includes lower alkyl substituted by 1 to 3 halogen atoms such as trifluoromethyl , trichloromethyl, tribromomethyl, 2, 2, 2-trifluoroethyl and 3,3,3-trifluoropropyl, in which more preferred one is trihalo( lower)alkyl.
- Optionally protected hydroxy(lower) alkyl includes hydroxy(lower)alkyl and protected hydroxy( lower)alkyl.
- Suitable examples of hydroxy-protecting group include lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, neopentyl, hexyl, etc.), acyl such as lower alkanoyl optionally substituted by one to three halogen atoms (e.g., formyl, acety1, propanoy1, butanoyl , 2-methylpropanoy1, pentanoyl, 2, 2-dimethylpropanoy1, hexanoyl, trichloroacetyl, trifluoroacetyl, etc.), optionally substituted phenyl ( lower) alkyl, for example, mono(or di or tri)
- Suitable "hydroxy(lower) alkyl” includes hydroxy(C ⁇ C alkyl such as hydroxymethy1, 1-hydroxyethy1, 2-hydroxyethyl, 1- hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 4-hydroxybutyl, 5-hydroxypentyl and 6-hydroxyhexyl.
- Suitable “protected hydroxy(lower)alkyl” includes lower alkoxy(lower)alkyl such as (C ⁇ C alkoxy(C ⁇ C alkyl, for example, methoxymethyl, 1-methoxyethyl, 2-methoxyethyl, 1-methoxypropyl, 2-methoxypropyl, 3-methoxypropyl, ethoxymethyl, 2-ethoxyethyl, 3- ethoxypropyl and propoxymethyl .
- lower alkoxy(lower)alkyl such as (C ⁇ C alkoxy(C ⁇ C alkyl, for example, methoxymethyl, 1-methoxyethyl, 2-methoxyethyl, 1-methoxypropyl, 2-methoxypropyl, 3-methoxypropyl, ethoxymethyl, 2-ethoxyethyl, 3- ethoxypropyl and propoxymethyl .
- Phenyl, pyridyl, thienyl or thiazolyl at R 2 is optionally substituted by one or more, preferably one to three, substituents selected from the group consisting of lower alkyl, lower alkoxy, halogen and trihalo( lower)alkyl.
- Suitable “amino-protecting group” includes, for example, acyl and conventional protecting group such as mono(or di or tri)aryl (lower) alkyl, for example, mono(or di or tri)phenyl (lower)alkyl (e.g., benzyl, trityl, etc.).
- acyl examples include aliphatic acyl such as lower alkanoyl which may be substituted by one to three halogen atoms (e.g., formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2- dimethylpropanoyl, hexanoyl, trichloroacetyl, trifluoroacetyl, etc.), lower alkoxycarbonyl (e.g., methoxycarbonyl , ethoxycarbonyl, tert-butoxycarbonyl, tert-pentyloxycarbonyl , etc.
- halogen atoms e.g., formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2- dimethylpropanoyl, hexanoyl, trichloroacetyl, triflu
- aryl (lower)alkoxycarbonyl e.g., phenyl ( lower) - alkoxycarbonyl (e.g., benzyloxycarbonyl , etc.), etc.] and the like.
- Suitable "carboxy-protecting group” includes, for example, lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec- butyl, isobutyl , tert-butyl, pentyl, neopentyl , hexyl , etc . ) , optionally substituted phenyl( lower)alkyl, for example, mono (or di or tri)phenyl (lower)alkyl which may be substituted by nitro (e.g., benzyl, 4-nitrobenzyl, benzhydryl, trityl, etc.) and the like.
- lower alkyl e.g., methyl, ethyl, propyl, isopropyl, butyl, sec- butyl, isobutyl , tert-butyl, pentyl, neopentyl , hexyl ,
- the object compound (I) of the present invention can be prepared by the following processes. Process . 1 )
- the starting compounds can be prepared by the following processes.
- R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are each as defined above, R 7 and R 8 are each amino-protecting group, and R 9 and R 10 are each carboxy-protecting group.
- the compound (I) or a salt thereof can be prepared by reacting the compound (II) or its reactive derivative at the carboxy group, or a salt thereof with the compound (III) or its reactive derivative at the amino group, or a salt thereof.
- Suitable reactive derivative of the compound (III) includes Schiff ' s base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (III) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (III) with a silyl compound such as N,0-bis(trimethylsilyl)acetamide, N- trimethylsilylacetamide or the like; a derivative formed by the reaction of the compound (III) with phosphorus trichloride or phosgene.
- Suitable reactive derivative of the compound (II) includes an acid halide, an acid anhydride and an activated ester.
- the suitable example may be an acid chloride; an acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.), dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, alkanesulfonic acid (e.g., methanesulfonic acid, ethanesulfonic acid, etc.), sulfuric acid, alkylcarbonic acid, aliphatic carboxylic acid (e.g., pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.); aromatic carboxylic acid (e.g., benzoic acid, etc
- the reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvents which do not adversely affect the reaction, or the mixture thereof.
- a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvents which do not adversely affect the reaction, or the mixture thereof.
- the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'- dicyclohexylcarbodiimide; N-cyclohexyl-N' -morpholinoethyl- carbodiimide; N-cyclohexyl-N' -(4-diethylaminocyclohexyl ) - carbodiimide; N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3- dimethylaminopropy1 )carbodiimide; N,N-carbonyl-bis- (2- methylimidazole) ; pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-l- chloroethylene; trialkyl phos
- the reaction may also be carried out in the presence of an organic or inorganic base such as an alkali metal bicarbonate, tri(lower)alkylamine, pyridine, N-( lower) alkylmorpholine, N,N- di( lower)alkylbenzylamine, or the like.
- an organic or inorganic base such as an alkali metal bicarbonate, tri(lower)alkylamine, pyridine, N-( lower) alkylmorpholine, N,N- di( lower)alkylbenzylamine, or the like.
- Process (2) is not critical, and the reaction is usually carried out under cooling to heating.
- the compound ( I ) or a salt thereof can be prepared by reacting the compound (IV) or its reactive derivative at the carboxy group, or a salt thereof with the compound (V) or a salt thereof.
- This reaction can be carried out in a similar manner to the reaction in the aforementioned Process ( 1 ) , and therefore the reagents to be used and reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process OX- Process (A)
- the compound (VII) or a salt thereof can be prepared by reacting the compound (VI) or its reactive derivative at the carboxy group, or a salt thereof with the compound (V) or a salt thereof.
- This reaction can be carried out in a similar manner to the reaction in the aforementioned Process ( 1 ) f and therefore the reagents to be used and reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process
- the compound (VIII) or a salt thereof can be prepared by subjecting the compound (VII) or a salt thereof to elimination reaction of the amino-protecting group.
- Suitable method of this elimination reaction includes conventional one such as hydrolysis, reduction and the like, (i) For hydrolysis:
- the hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.
- Suitable base includes an inorganic base and an organic base such as an alkali metal (e.g., sodium, potassium, etc.), an alkaline earth metal (e.g., magnesium, calcium, etc.), the hydroxide or carbonate or hydrogencarbonate thereof, trialkylamine (e.g., trimethylamine, triethylamine, etc.), picoline, l,5-diazabicyclo[4.3.0]non-5-one, or the like.
- alkali metal e.g., sodium, potassium, etc.
- an alkaline earth metal e.g., magnesium, calcium, etc.
- trialkylamine e.g., trimethylamine, triethylamine, etc.
- picoline l,5-diazabicyclo[4.3.0]non-5-one, or the like.
- Suitable acid includes an organic acid (e.g., formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.), and an inorganic acid (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.).
- organic acid e.g., formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.
- an inorganic acid e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen chloride, hydrogen bromide, etc.
- Lewis acid such as trihaloacetic acid (e.g., trichloroacetic acid, trifluoroacetic acid, etc.), or the like is preferably carried out in the presence of cation trapping agents (e.g., anisole, phenol, etc.). This reaction is usually carried out without solvent.
- cation trapping agents e.g., anisole, phenol, etc.
- the reaction may be carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide or any other organic solvents which do not adversely affect the reaction, or a mixture thereof.
- a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide or any other organic solvents which do not adversely affect the reaction, or a mixture thereof.
- reaction temperature is not critical and the reaction is usually carried out under cooling to warming, (ii) For reduction:
- Reduction is carried out in a conventional manner, including chemical reduction and catalytic reduction.
- Suitable reducing reagent to be used in chemical reduction are hydrides (e.g., hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, etc.), or a combination of a metal (e.g., tin, zinc, iron, etc.) or metallic compound (e.g., chromium chloride, chromium acetate, etc.) and an organic acid or inorganic acid (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, p- toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.).
- a metal e.g., tin, zinc, iron, etc.
- metallic compound e.g., chromium chloride, chromium acetate, etc.
- organic acid or inorganic acid e.g., formic acid, acetic acid, propionic acid,
- Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, palladium hydroxide on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g., reduced nickel, nickel oxide, Raney nickel , etc . ) , cobalt catalysts (e.g., reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g., reduced iron, Raney iron, Ullman iron, etc.), and the like.
- platinum catalysts e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.
- palladium catalysts e.g.,
- the reduction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N- dimethylforma ide, N,N-dimethylacetamide or any other organic solvents which do not adversely affect the reaction, or a mixture thereof.
- a solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N- dimethylforma ide, N,N-dimethylacetamide or any other organic solvents which do not adversely affect the reaction, or a mixture thereof.
- alcohol e.g., methanol, ethanol, isopropyl alcohol, etc
- the compound (X) or a salt thereof can be prepared by reacting the compound (IX) or its reactive derivative at the carboxy group, or a salt thereof with the compound (VIII) or its reactive derivative at the amino group, or a salt thereof.
- This reaction can be carried out in a similar manner to the reaction in the aforementioned Process ( 1 ) f and therefore the reagents to be used and reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process
- the compound (III) or a salt thereof can be prepared by subjecting the compound (X) or a salt thereof to elimination reaction of the amino-protecting group.
- This reaction can be carried out in a similar manner to the reaction in the aforementioned Process (B) , and therefore the reagents to be used and reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process
- the compound (XII) or a salt thereof can be prepared by reacting the compound (II) or its reactive derivative at the carboxy group, or a salt thereof with the compound (XI) or its reactive derivative at the amino group, or a salt thereof.
- This reaction can be carried out in a similar manner to the reaction in the aforementioned Process ( 1 ) , and therefore the reagents to be used and reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process ox-
- the compound (XIII) or a salt thereof can be prepared by subjecting the compound (XII) or a salt thereof to elimination reaction of the carboxy-protecting group.
- This reaction can be carried out in a similar manner to the reaction in the aforementioned Process (B) f and therefore the reagents to be used and reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process
- the compound (XV) or a salt thereof can be prepared by reacting the compound (XIII) or its reactive derivative at the carboxy group, or a salt thereof with the compound (XIV) or its reactive derivative at the amino group, or a salt thereof.
- This reaction can be carried out in a similar manner to the reaction in the aforementioned Process ( 1 ) , and therefore the reagents to be used and reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process -OX-
- the compound (IV) or a salt thereof can be prepared by subjecting the compound (XV) or a salt thereof to elimination reaction of the carboxy-protecting group.
- This reaction can be carried out in a similar manner to the reaction in the aforementioned Process (B) f and therefore the reagents to be used and reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process
- the compound (XVI) or a salt thereof can be prepared by reacting the compound (IX) or its reactive derivative at the carboxy group, or a salt thereof with the compound (XIV) or its reactive derivative at the amino group, or a salt thereof.
- This reaction can be carried out in a similar manner to the reaction in the aforementioned Process ( 1 ) , and therefore the reagents to be used and reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process -OX- Process (J)
- the compound (XVII) or a salt thereof can be prepared by subjecting the compound (XVI) or a salt thereof to elimination reaction of the amino-protecting group.
- This reaction can be carried out in a similar manner to the reaction in the aforementioned Process (B) f and therefore the reagents to be used and reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process
- the compound (XV) or a salt thereof can be prepared by reacting the compound (II) or its reactive derivative at the carboxy group, or a salt thereof with the compound (XVII) or its reactive derivative at the amino group, or a salt thereof.
- This reaction can be carried out in a similar manner to the reaction in the aforementioned Process ( 1 ) f and therefore the reagents to be used and reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of Process -OX-
- Suitable salts of the starting compounds and their reactive derivatives in Processes (1) and (2) and Processes (A) to (K) can be referred to the ones as exemplified for the compound (I).
- the compounds obtained by the above process can be isolated and purified by a conventional method such as pulverization, recrystallization, column chromatography, reprecipitation, or the like.
- the compound (I) and the other compounds may include one or more stereoisomer(s) such as optical isomer(s) and geometrical isomer(s) due to asymmetric carbon atom(s) and double bond(s), and all of such isomers and mixtures thereof are included within the scope of this invention.
- the object compounds (I) and pharmaceutically acceptable salts thereof include solvates [e.g., enclosure compounds (e.g., hydrate, etc. ) ] .
- the object compounds (I) and pharmaceutically acceptable salts thereof possess a strong inhibitory activity on the production of nitric oxide (NO).
- the object compounds (I) and pharmaceutically acceptable salts thereof are expected to possess a nitric oxide synthase (NOS)-inhibitory activity or a NOS-production inhibitory activity.
- NOS nitric oxide synthase
- the object compounds (I) and pharmaceutically acceptable salts thereof are useful for prevention and/or treatment of NO-mediated diseases in human being and animals, including respiratory diseases such as adult respiratory distress syndrome (ARDS) and asthma; cardiovascular diseases such as cardiovascular ischemia, myocarditis, heart failure, hypotension and atherosclerosis; endocrine diseases such as diabetes (e.g., insulin-dependent diabetes mellitus, etc.), complications of diabetes mellitus (e.g., diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, etc.) and gout; renal diseases such as glomerulonephritis and renal failure; gastrointestinal diseases such as peptic ulcer and inflammatory bowel disease (e.g., ulcerative colitis, chronic colitis, etc.); pancreatic diseases such as pancreatitis; hepatic diseases such as hepatitis and liver cirrhosis; diseases of bone or joint such as synovitis, arthritis, osteoarthritis, osteoporosis; autoimmune diseases such as
- the object compounds (I) and pharmaceutically acceptable salts thereof are also useful for prevention and/or treatment of NO-mediated nervous diseases including central nervous system diseases such as CNS disorders, cerebrovascular diseases (e.g., cerebral infarction, cerebral ischemia, cerebral hemorrhage, etc.), migraine, Alzheimer's disease; peripheral nervous system diseases such as neuritis, pain (e.g., postherpetic neuralgia, reflex sympathetic dystrophy (RSD), causalgia, deafferentation pain syndrome, neuropathic pain, etc.), allodynia, hyperalgesia, neurological disorders and neuroprotection; Parkinson's disease; and amyotrophic lateral sclerosis.
- central nervous system diseases such as CNS disorders, cerebrovascular diseases (e.g., cerebral infarction, cerebral ischemia, cerebral hemorrhage, etc.), migraine, Alzheimer's disease
- peripheral nervous system diseases such as neuritis, pain (e.g., postherpetic neuralgia, reflex sympathetic dystrophy (RSD
- object compounds (I) and pharmaceutically acceptable salts thereof are useful for treatment of sexual dysfunction such as male sexual dysfunction including erectile dysfunction, and female sexual dysfunction including orgasmic dysfunction related to clitoral disturbances.
- the object compounds (I) and pharmaceutically acceptable salts thereof are useful for prevention and/or treatment of NO-mediated ophthalmic diseases, including conjunctive diseases such as conjunctivitis (e.g., allergic conjunctivitis, vernal conjunctivitis, keratoconjunctivitis sicca, viral conjunctivitis, bacterial conjunctivitis, etc.); uveal diseases such as uveitis (e.g., Behcet disease, Harada disease, sympathetic ophthalmia, sarcoidosis, diabetic blinkis, etc.); scleral diseases such as scleritis; corneal diseases such as corneal neovascularization, keratitis, corneal edema, corneal opacity, corneal dystrophy, keratoconus and neuroparalytic keratitis; retinal, vitreous diseases such as diabetic retinopathy, retinal artery occlusion, retinal vein occlusion
- Test 1 Assay for inhibitory activity on the production of nitric oxide
- RAW264.7 The murine macrophage cell line RAW264.7 (American Type Culture Collection, No. TIB71) was used in this study.
- RAW264.7 cells were grown on F75 plastic culture flasks at 37°C, 5% in Dulbecco's modified Eagle's medium (DMEM) supplemented with L- glutamine, penicillin, streptomycin and 10% heat-inactivated fetal bovine serum. They were removed from culture flasks by rubber cell scraper and were centrifuged and resuspended in DMEM without phenol red. They were plated in 96-well microtiter plates (10 5 cells per well) and allowed to adhere over 2 hours. The test samples were added and the cells were preincubated for 1 hour.
- DMEM Dulbecco's modified Eagle's medium
- LPS lipopolysaccharide
- INF 7 interferon 7
- Test 2 Protective effect of the compound (I) combined with FK506 on rat cardiac allograft Method:
- Rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.), and underwent allogeneic (Lewis donor to ACI recipient) heterotopic cardiac transplantation.
- Experimental groups were divided into single-drug group and combined-drug group.
- Combined-drug dose was FK506 (0.32 mg/kg) + the compound (I) (10 mg/kg).
- the grafted hearts were monitored by daily palpation where complete rejection was defined as the cessation of palpable contractile activity.
- Each drug was suspended in a solution of 0.5% methylcellulose, and administered by daily gastric intubation in a volume of 5 ml/kg of body weight for 14 days.
- the object compound (I) of the present invention and pharmaceutically acceptable salts thereof are used in the form of a conventional pharmaceutical preparation in admixture with a conventional pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient which is suitable for oral, parenteral or external administration.
- a conventional pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient which is suitable for oral, parenteral or external administration.
- the pharmaceutical preparation may be compounded in a solid form such as granule, capsule, tablet, dragee, suppository or ointment, or in a liquid form such as solution, suspension or emulsion for injection, intravenous drip, ingestion, eye drop, etc. If needed, there may be included in the above preparation auxiliary substance such as stabilizing agent, wetting or emulsifying agent, buffer or any other commonly used additives .
- the effective ingredient may usually be administered in a unit dose of 0.001 mg/kg to 500 mg/kg, preferably 0.01 mg/kg to 10 mg/kg, 1 to 4 times a day.
- the above dosage may be increased or decreased according to age, body weight and conditions of the patient or administering method.
- a pharmaceutical composition comprising FK506 and the compound (I) or a pharmaceutically acceptable salt thereof.
- a pharmaceutical composition comprising FK506 and the compound (I) or a pharmaceutically acceptable salt thereof is useful as an immunosuppressant.
- the pharmaceutical composition of the present invention is useful for the prevention or treatment of rejection by organ transplantation.
- a ratio by weight of the compound (I) or a pharmaceutically acceptable salt thereof to FK506 is in the range of 0.1/1 - 1000/1, preferably in the range of 1/1 - 100/1.
- the preferred embodiments of the amide compound of the present invention represented by the general formula (I) are as follows .
- the mixture was stirred at 7-10°C for 30 minutes and at room temperature for 2 hours.
- the mixture was diluted with saturated aqueous sodium hydrogencarbonate solution and extracted with ethyl acetate.
- the aqueous layer was extracted with two 500-ml portions of ethyl acetate, and the combined organic layers were extracted with IN hydrochloric acid (150 ml x 2).
- the combined aqueous layers were basified (pH 9) with sodium hydrogencarbonate and extracted with ethyl acetate.
- the organic layer was washed thoroughly with aqueous sodium hydrogencarbonate solution and brine, dried over magnesium sulfate and concentrated in vacuo to give the title compound (42 g).
- reaction mixture was diluted with ethyl acetate (15 ml), and washed successively with saturated aqueous sodium hydrogencarbonate solution, water, and brine.
- the organic layer was dried over magnesium sulfate, and the solvent was removed under reduced pressure.
- the residue was purified by silica gel column chromatography (chloroform- methanol 10:1) to give the title compound as a colorless amorphous solid.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/111,412 US6825200B1 (en) | 1999-11-04 | 2000-10-27 | Substituted dipeptides having nos inhibiting activity |
EP00970164A EP1226159A1 (en) | 1999-11-04 | 2000-10-27 | Substituted dipeptides having nos inhibiting activity |
JP2001535389A JP2003513104A (en) | 1999-11-04 | 2000-10-27 | Substituted dipeptides having NOS inhibitory activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPQ3868 | 1999-11-04 | ||
AUPQ3868A AUPQ386899A0 (en) | 1999-11-04 | 1999-11-04 | Peptide compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001032690A1 true WO2001032690A1 (en) | 2001-05-10 |
Family
ID=3818016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/007579 WO2001032690A1 (en) | 1999-11-04 | 2000-10-27 | Substituted dipeptides having nos inhibiting activity |
Country Status (5)
Country | Link |
---|---|
US (1) | US6825200B1 (en) |
EP (1) | EP1226159A1 (en) |
JP (1) | JP2003513104A (en) |
AU (1) | AUPQ386899A0 (en) |
WO (1) | WO2001032690A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002055541A3 (en) * | 2001-01-02 | 2003-08-07 | Fujisawa Pharmaceutical Co., Ltd. | Peptides having inhibiting activity on the production of nitric oxide |
DE102004032567A1 (en) * | 2004-07-05 | 2006-03-02 | Grünenthal GmbH | Substituted 1-propiolyl-piperazines |
EP1973880B1 (en) * | 2006-01-27 | 2013-08-07 | Bristol-Myers Squibb Company | Piperazinyl derivatives as modulators of chemokine receptor activity |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996016981A2 (en) * | 1994-12-02 | 1996-06-06 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds for prevention and/or treatment of no-mediated diseases |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000511173A (en) | 1996-05-27 | 2000-08-29 | 藤沢薬品工業株式会社 | Novel indolyl and benzofuranylcarboxamides as inhibitors of nitric oxide production |
-
1999
- 1999-11-04 AU AUPQ3868A patent/AUPQ386899A0/en not_active Abandoned
-
2000
- 2000-10-27 EP EP00970164A patent/EP1226159A1/en not_active Withdrawn
- 2000-10-27 US US10/111,412 patent/US6825200B1/en not_active Expired - Fee Related
- 2000-10-27 WO PCT/JP2000/007579 patent/WO2001032690A1/en active Search and Examination
- 2000-10-27 JP JP2001535389A patent/JP2003513104A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996016981A2 (en) * | 1994-12-02 | 1996-06-06 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compounds for prevention and/or treatment of no-mediated diseases |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002055541A3 (en) * | 2001-01-02 | 2003-08-07 | Fujisawa Pharmaceutical Co., Ltd. | Peptides having inhibiting activity on the production of nitric oxide |
US7129243B2 (en) | 2001-01-02 | 2006-10-31 | Astellas Pharma Inc. | Peptide compounds |
DE102004032567A1 (en) * | 2004-07-05 | 2006-03-02 | Grünenthal GmbH | Substituted 1-propiolyl-piperazines |
US7300939B2 (en) | 2004-07-05 | 2007-11-27 | Gruenenthal Gmbh | Substituted 1-propiolylpiperazine compounds, their preparation and use |
EP1973880B1 (en) * | 2006-01-27 | 2013-08-07 | Bristol-Myers Squibb Company | Piperazinyl derivatives as modulators of chemokine receptor activity |
US8609664B2 (en) | 2006-01-27 | 2013-12-17 | Bristol-Myers Squibb Co. | Piperazinyl derivatives as modulators of chemokine receptor activity |
Also Published As
Publication number | Publication date |
---|---|
AUPQ386899A0 (en) | 1999-11-25 |
EP1226159A1 (en) | 2002-07-31 |
JP2003513104A (en) | 2003-04-08 |
US6825200B1 (en) | 2004-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5468731A (en) | Peptide compounds, a process for preparation thereof and pharmaceutical composition comprising the same | |
KR100381535B1 (en) | Piperazine derivatives | |
WO2016115090A1 (en) | Compounds, compositions and methods for increasing cftr activity | |
WO1998016527A1 (en) | Benzoxepine derivatives which promote release of growth hormone | |
WO2016105468A1 (en) | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis | |
NO173014B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE BENZODIAZEPINE DERIVATIVES | |
US5633232A (en) | Tachykinin antagonist dipeptides | |
AU2016297886A1 (en) | Compounds, compositions and methods of increasing CFTR activity | |
EP0914322A1 (en) | New indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production | |
US6825200B1 (en) | Substituted dipeptides having nos inhibiting activity | |
CA2433582C (en) | Peptides having inhibiting activity on the production of nitric oxide | |
WO2001060808A1 (en) | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | |
EP1196407A1 (en) | N-imidazolylmethyl carboxamides as nitric oxide production inhibitors | |
AU2002222675A1 (en) | Peptides having inhibiting activity on the production of nitric oxide | |
JPH08337579A (en) | Guanidinothiazole and its use as antiulcerous agent, h2-receptor antagonistic agent and antimicrobial agent | |
JPH1045751A (en) | New piperazine compound | |
AU7675098A (en) | Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists | |
JPH1081671A (en) | New peptide compound | |
AU2001234097A1 (en) | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): BR CA CN JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 535389 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000970164 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10111412 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000970164 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000970164 Country of ref document: EP |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |